Atirmociclib - Pfizer
Alternative Names: PF-07220060Latest Information Update: 23 Aug 2024
At a glance
- Originator Pfizer
- Class Amines; Antineoplastics; Benzimidazoles; Cyclic ethers; Halogenated hydrocarbons; Propanols; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III HER2 negative breast cancer
- Phase II Breast cancer; Solid tumours
- Phase I Prostate cancer
Most Recent Events
- 31 Jul 2024 Phase-II clinical trials in Breast cancer (Early-stage disease) (PO) before July 2024 (Pfizer pipeline, July 2024)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA
- 19 Jul 2024 Pfizer completes a phase I trial (In volunteers) in USA (PO, Tablet) (NCT05923411)